Table 1.
Clinical characteristics for the study population
| Batch 1 (N = 132) | Batch 2 (N = 296) | Total (N = 428) | |
|---|---|---|---|
|
EOC status |
|
|
|
| Control |
66 (50.0%) |
148 (50.0%) |
214 (50.0%) |
| Case |
66 (50.0%) |
148 (50.0%) |
214 (50.0%) |
|
Age |
|
|
|
| Mean (SD) |
60 (12) |
63 (13) |
62 (13) |
| Median |
61 |
65 |
64 |
| Q1, Q3 |
50, 69 |
54, 73 |
52, 72 |
| Range |
(33–82) |
(27–91) |
(27–91) |
|
Year enrolled |
|
|
|
| 1999–2002 |
18 (13.6%) |
164 (55.4%) |
182 (42.5%) |
| 2003 |
10 (7.6%) |
36 (12.2%) |
46 (10.7%) |
| 2004 |
41 (31.1%) |
33 (11.1%) |
74 (17.3%) |
| 2005 |
25 (18.9%) |
23 (7.8%) |
48 (11.2%) |
| 2006–2007 |
38 (28.8%) |
40 (13.5%) |
78 (18.2%) |
|
Parity, number of births |
|
|
|
| Nulliparous |
24 (18.2%) |
42 (14.2%) |
66 (15.4%) |
| 1-2,<=20 yrs |
7 (5.3%) |
14 (4.7%) |
21 (4.9%) |
| 1-2,>20 yrs |
31 (23.5%) |
84 (28.4%) |
115 (26.9%) |
| 3+,<=20 yrs |
28 (21.2%) |
47 (15.9%) |
75 (17.5%) |
| 3+,>20 yrs |
40 (30.3%) |
95 (32.1%) |
135 (31.5%) |
|
Smoking status (current) |
|
|
|
| No |
120 (90.9%) |
259 (87.5%) |
379 (88.6%) |
| Yes |
10 (7.6%) |
19 (6.4%) |
29 (6.8%) |
|
State |
|
|
|
| Other |
68 (51.5%) |
120 (40.5%) |
188 (43.9%) |
| Minnesota |
64 (48.5%) |
176 (59.5%) |
240 (56.1%) |
|
Alcohol consumption |
|
|
|
| Never |
32 (24.2%) |
71 (24.0%) |
103 (24.1%) |
| Current |
78 (59.1%) |
152 (51.4%) |
230 (53.7%) |
| Former |
18 (13.6%) |
47 (15.9%) |
65 (15.2%) |
|
Histology |
|
|
|
| Serous |
43 (65.2%) |
98 (66.2%) |
141 (65.9%) |
| Mucinous |
1 (1.5%) |
4 (2.7%) |
5 (2.3%) |
| Endometrioid |
16 (24.2%) |
33 (22.3%) |
49 (22.9%) |
| Clear Cell |
4 (6.1%) |
9 (6.1%) |
13 (6.1%) |
| Other |
2 (3.0%) |
4 (2.7%) |
6 (2.8%) |
|
Grade |
|
|
|
| Grade 1 |
1 (1.6%) |
9 (6.1%) |
10 (4.7%) |
| Grade 2 |
10 (15.6%) |
21 (14.2%) |
31 (14.6%) |
| Grade 3 |
32 (50.0%) |
79 (53.4%) |
111 (52.4%) |
| Grade 4 |
21 (32.8%) |
39 (26.4%) |
60 (28.3%) |
|
Stage |
|
|
|
| Stage 1 |
11 (16.7%) |
29 (19.6%) |
40 (18.7%) |
| Stage 2 |
3 (4.5%) |
11 (7.4%) |
14 (6.5%) |
| Stage 3 |
43 (65.2%) |
84 (56.8%) |
127 (59.3%) |
| Stage 4 | 9 (13.6%) | 24 (16.2%) | 33 (15.4%) |